Thirty subjects participated in a nine-period , randomized , double-blinded , placebo-controlled , crossover , ascending dose , first-in-human study with i.v. infusions of 0.1-0 .96 mg kg ( -1 ) h ( -1 ) for 1 h and intermediate doses up to 4 h.